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Abstract
Background: Liver diseases are major global health problems. Ginseng extract has antioxidant, immune-modulatory
and anti-inflammatory activities. This study investigated the effect of ginseng extract on carbon tetrachloride (CCl4)-
induced liver fibrosis in rats.
Methods: Male Wistar rats were divided into four groups: control group, ginseng group, CCl4 group and CCl4 +
ginseng group. Liver injury was induced by the intraperitoneal (I.P) injection of 3 ml/kg CCl4 (30% in olive oil)
weekly for 8 weeks. The control group was I.P injected with olive oil. The expression of genes encoding
transforming growth factor beta (TGF-β), type I TGF-β receptor (TβR-1), type II TGF-β receptor (TβR-II), mothers
against decapentaplegic homolog 2 (Smad2), Smad3, Smad4, matrix metalloproteinase 2 (MMP2), MMP9, tissue
inhibitor matrix metalloproteinase-1 (TIMP-1), Collagen 1a2 (Col1a2), Collagen 3a1 (Col3a1), interleukin-8 (IL-8) and
interleukin -10 (IL-10) were measured by real-time PCR.
Results: Treatment with ginseng extract decreased hepatic fat deposition and lowered hepatic reticular fiber
accumulation compared with the CCl4 group. The CCl4 group showed a significant increase in hepatotoxicity
biomarkers and up-regulation of the expression of genes encoding TGF-β, TβR-I, TβR-II, MMP2, MMP9, Smad-2,-
3, -4, and IL-8 compared with the control group. However, CCl4 administration resulted in the significant
down-regulation of IL-10 mRNA expression compared with the control group. Interestingly, ginseng extract
supplementation completely reversed the biochemical markers of hepatotoxicity and the gene expression
alterations induced by CCl4.
Conclusion: ginseng extract had an anti‐fibrosis effect via the regulation of the TGF‐β1/Smad signaling
pathway in the CCl4‐induced liver fibrosis model. The major target was the inhibition of the expression of
TGF‐β1, Smad2, and Smad3.
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Background
The liver plays a key role in various pathological disorders
such as fatty liver, hepatic virus infection, chemical hepa-
totoxins, and toxicity cases [1, 2]. Several hepatotoxicants
including polycyclic aromatic hydrocarbons, nitrosamines,
and carbon tetrachloride (CCl4) are transformed into
intermediate reactive oxygen species that have hepatotoxic
effects in humans and experimental animal models [3].
For models of human disease, the rat offers many advan-
tages over mice and other organisms, including the size of
its body and substructures in organs, as well as the ability
to measure drug effects at specific anatomical areas [1].
Chronic liver diseases are worldwide health problems
causing approximately 800,000 deaths per year [2, 3]. Of
these, liver fibrosis is caused by inflammation and the
excessive accumulation of the extracellular matrix. Sub-
sequently, cirrhosis occurs and can cause hepatocellular
carcinoma [4]. Although advanced fibrosis is reversible
depending on the degree of fibrosis, end-stage cirrhosis
is irreversible [5].
The inhibition of hepatic inflammation and fibrosis is
crucial in preventing cirrhosis and HCC. However, the
currently used methods for fibrosis evaluation are inva-
sive such as liver biopsy or non-invasive including serum
and genetic tests, and imaging techniques [6].
Carbon tetrachloride (CCl4) is a hepatotoxin that
targets both the liver and kidneys. CCl4 is activated
in the liver to highly reactive trichloromethyl radicals
that initiate the free radical-mediated lipid peroxida-
tion of membrane phospholipids, causing functional
and morphological changes in the cell membrane,
which stimulate hepatotoxicity, fibrosis [7], cirrhosis
and HCC in animal species [8]. Reactive oxygen spe-
cies results in oxidative stress that plays a significant
role in liver fibrogenesis [9]. Tri-chloromethyl radicals
produced from CCl4 metabolism initiate reactions that
cause liver steatosis, fibrosis or cirrhosis [9] via the
activation of cytokines such as interleukin (IL)-1,
tumor necrosis factor (TNF)-α, and transforming
growth factor (TGF)-β expression, and the inhibition
of nitric oxide (NO) formation [10–12].
Activated TGF-β stimulated the over expression of
many extracellular matrix (ECM) proteins and sup-
pressed their degradation by matrix metalloproteinases
(MMP) via the upregulation of tissue inhibitor of metal-
loproteinases (TIMP) [13]. Binding of TGF-β to TGF-β
receptor–II (TβR-II) triggers signals mediated by the
phosphorylation of receptor associated Smads (Smad2
and Smad3; R-Smads), which then form a complex with
Smad4 that enters the nucleus and binds to the TGF-β
promoter to regulate its expression [14].
Panax ginseng root is used in oriental medicine, diets
or as a dietary supplement. Ginseng has a variety of bene-
ficial biological properties including anti-diabetic, anti-
carcinogenic, anti-inflammatory, and neuro-protective
effects [15]. The pharmacological properties of ginseng
are mainly attributed to ginsenosides, which are phen-
olic acids, flavonoids, and triterpenoid saponins [16].
Ginsenosides are bioactive compounds such as Rb1,
Rb2, Rg1, Rd, and Re [10, 17] that have antioxidant
and anti-inflammatory effects [18] via different mech-
anisms and pathways in vitro, in vivo, and in clinical
models [19].
Many studies have shown that ginseng attenuates liver
injury by inhibiting lipid peroxidation, as well as TNF-α,
NO, prostaglandin E2 (PGE2), intercellular adhesion
molecule (ICAM)-1 and nuclear factor-κB (NF-κB) acti-
vation [14, 20–22]. However, the pharmacological effects
of ginseng/ginsenosides on liver disorders, especially
liver fibrosis, are not clear. Therefore, the aim of this
study was to investigate the effect of ginseng extract on
CCl4-induced liver inflammation and fibrosis in rats.
Methods
The present study was performed and described accord-
ing to the Animal Research: Reporting In Vivo Experi-
ments (ARRIVE) statement [23].
Chemicals
CCl4 and ginseng (Panax ginseng) were purchased from
Sigma Chemicals (Sigma-Aldrich, St. Louis, MO, USA).
Carbon tetrachloride was dissolved in olive oil, an emul-
sifying agent that allows CCl4 to dissolve sufficiently to
induce liver damage. In addition, olive oil has no toxicity
or other biological or pharmacological activity with re-
gard to hepatotoxicity. Ginseng was dissolved in water
and administrated by oral gavage. The SYBR® Green
PCR Master Mix kit was purchased from Applied Bio-
systems (Life Technologies, Grand Island, NY, USA).
Primers used in this study were designed using Primer
Express 3.0 software (Applied Biosystem, Life Technolo-
gies, Grand Island, NY, USA) and synthesized by Meta-
bion International AG (Planegg, Germany). Aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT) measurement kits were purchased from Human
(Human, Wiesbaden, Germany).
Study animals
Six-week-old male Wistar rats with a mean body weight of
180–200 g were obtained from the Animal Care Center,
College of Pharmacy, King Saud University, Riyadh, Saudi
Arabia. The animals were kept under standard conditions
of temperature (22 ± 1 °C), humidity (50–55%), and a 12 h
light/dark cycle, with free access to standard laboratory
feed and water according to the study protocol. All
methods were conducted in accordance with the Guide for
Care and Use of Laboratory Animals, Institute for Labora-
tory Animal Research, National Institute of Health (NIH
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publication No. 80–23; 1996). The study was approved by
the Experimental Animal Care Center Review Board (num-
ber E.A.C.P -6140/2016), King Saud University Riyadh,
Saudi Arabia.
Experimental design
The experimental design was based on a previous proto-
col [24, 25]. Forty adult male Wistar rats were randomly
divided into four groups of 10 animals each as follows.
1. Group I: the control group received 3 mL/kg olive
oil twice a week for 8 weeks.
2. Group II: the ginseng group received 400 mg/kg/day
ginseng dissolved in water administrated by oral
gavage for 8 weeks.
3. Group III: the CCl4 group received 3 ml/kg CCl4
intraperitoneal (30% in olive oil) twice a week for
8 weeks and normal drinking water.
4. Group IV: the CCl4-ginseng group received 3 ml/kg
CCl4 (30% in olive oil) twice a week for 8 weeks and
400 mg/kg/day ginseng dissolved in water and
administrated by oral gavage one week before the
first dose of CCl4 and continuously to the end of the
protocol.
At least 24 h after the last treatment, blood samples
were collected via cardiac puncture under anesthesia
and centrifuged to separate the sera. Then the animals
were euthanized by decapitation. The sera were sepa-
rated and kept at −80 °C until used. The liver was imme-
diately removed and divided into sections that were
either washed with ice-cold saline solution, snap frozen
in liquid nitrogen and stored until used for gene expres-
sion analysis, or cut into small pieces of 0.5–2.0 cm
thick for histopathological study.
Histopathological study
Samples of livers from control and experimental groups
were fixed in 10% neutral buffered formalin. The stand-
ard method of dehydration, clearing in xylene, and paraf-
fin embedding was used. Sections of 5-μm thickness
were cut by a rotary microtome and stained with Mas-
son’s Trichrome (Bancroft and Gamble 2008). Sections
were examined by light microscopy.
Liver biological activities
Blood from the heart was collected into coagulant tubes,
left to coagulate, and then centrifuged at 3000 × g for
15 min at 4 °C. Serum ALT and AST activities were mea-
sured spectrophotometrically using a commercial kit
(Human, Wiesbaden, Germany).
Serum and hepatic triglycerides (TG), total cholesterol
(TC), low-density lipoprotein (LDL), and high-density
lipoprotein (HDL) concentrations were measured using
commercial enzymatic kits (Randox® TR213 for triglyc-
erides, Randox® CH201 for total cholesterol, Randox
Laboratories Ltd., London, UK).
Liver samples were homogenized in a chloroform/
methanol (2:1) solution to a final dilution 20 times the
volume of tissues for at least 3 min and extracted with a
chloroform/methanol/water (3:48:47) solution [26].
Measurement of gene expression by real-time PCR
Total RNA was extracted from liver tissues using a Total
RNA Miniprep Kit (Axygen, Bioscience, Central Avenue,
Union, USA) according to the manufacturer’s protocol.
The RNA concentrations and purity were measured by
NanoDrop (NanoDrop 8000, Thermo Scientific, USA).
The extracted RNA had a 260/280 ratio of 1.9–2.1.
cDNA was synthesized from 1 μg RNA using a high cap-
acity cDNA reverse transcription kit as described in the
manufacturer’s protocol (Applied Biosystems, Life Tech-
nologies, Grand Island, NY, USA).
Real-time quantitative PCR (SYBR® Green PCR Master
Mix kit, Applied Biosystems, Life Technologies, Grand
Island, NY, USA) was used to detect the expression
levels of transforming growth factor beta (TGF-β), type I
TGF-β receptor (TβR-1), type II TGF-β receptor (TβR-
II), mothers against decapentaplegic homolog 2 (Smad2),
Smad3, Smad4, matrix metalloproteinase2 (MMP2),
MMP9, tissue inhibitor matrix metalloproteinase-1
(TIMP-1), Collagen 1a2 (Col1a2), Collagen 3a1 (Col3a1),
IL-8 (IL-8) and IL-10 (IL-10) genes in liver tissues.
GAPDH was used as an internal control. The reaction
was performed on ABI 7500 Detection System (Applied
Biosystems, Life Technologies, Grand Island, NY, USA).
The program was set to run for one cycle at 95 °C for
2 min, followed by 40 cycles at 95 °C for 15 s and 60 °C
for 1 min. The specificity of amplification was confirmed
by melting curve analysis. The primer sequences used in
this study are shown in Table 1. The gene expression
results were analyzed using the 2-ΔΔCT method [27].
Data were expressed as the mean fold change ± standard
error for three independent amplifications.
Statistical analyses
The differences between the obtained values (mean ±
SEM, n = 10) were assessed by one-way analysis of vari-
ance (ANOVA) followed by Tukey–Kramer multiple com-
parison using Graph Pad Prism five software (GraphPad
Software, Inc., La Jolla, CA, USA). The differences were
considered statistically significant when p <0.05.
Results
Liver enzyme (ALT and AST) levels in sera were used as
biochemical markers for early acute hepatotoxicity. The
CCl4 group showed a significant increase in the levels of
AST (112.3 ± 3.5 U/L) (Fig. 1a) and ALT (135.6 ± 5.2 U/L)
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(Fig. 1b) compared with the control group (48.9 ± 2.8 U/L
and 52.2 ± 2.2 U/L, respectively) (p <0.001). However, gin-
seng restored liver enzyme levels to values similar to the
control group.
CCl4 significantly increased serum lipid parameters
including TG, TC and LDL levels and nonsignificantly
decreased the HDL level compared with the control
group. Ginseng supplementation in combination with
CCl4 significantly decreased TC and LDL levels compared
with the CCl4 group. No effect of ginseng alone on TG,
TC, HDL, and LDL levels was observed (Table 2).
Histopathological examination of the liver
Histopathological abnormalities in the liver were studied
at the end of the experiment using Masson’s trichrome
staining. The effects of CCl4, ginseng, and CCl4 + gin-
seng on histopathological changes in the liver, especially
in liver fibrosis, are shown in Fig. 2.
In the control group (GI), all features of the liver were
observed to be normal (hepatic lobules with central
veins, hepatic strands of hepatocytes, portal area, and
blood sinusoids) (Fig. 2a, b). Animals in group II who
received ginseng dissolved in water showed no histo-
logical evidence of pathological alterations (Fig. 2c, d,).
In the CCl4-treated group (GIII), the liver showed clas-
sical fibrosis around the congested central vein (Fig. 2e)
and portal area, which was accompanied by a variable
degree of proliferated bile duct (Fig. 2g). The normal
architecture of the hepatic lobules were lost (Fig. 2f ),
and fibroid collapsed blood sinusoids were demon-
strated. Hydropic degeneration, vacuolization (Fig. 2c),
and fatty hepatocytes were observed (Fig. 2d).
In the CCl4 and ginseng group (GIV), the normal
architecture of hepatic lobules was observed (Fig. 2h).
The hepatic strands were composed of atypical polyhe-
dral hepatocytes with a distinct nucleus and prominent
nucleolus. A reduction of fatty hepatocytes, vacuoles,
and collagen fibers especially around the central vein
were detected (Fig. 2i).
The effect of CCl4, ginseng, and CCl4 + ginseng on TGF-
β, TβF-I, and TβF-II expression is shown in Fig. 3. The ex-
pressions of TGF-β, TβF-I, and TβF-II in the CCl4 group
were increased significantly by 7.6, 9.2 and 7.3-fold, re-
spectively, compared with the control group (p <0.001).






















































Fig. 1 Effect of CCl4, Ginseng, and CCl4 + Ginseng on the serum levels of AST (a) and ALT (b). Data are presented as the mean ± SEM (n = 10). *, #
and $ indicate a significant change from control, Ginseng and CCl4 + Ginseng groups, respectively (p <0.05 using ANOVA followed by
Tukey—Kramer as a post ANOVA test)
Table 1 Primers used in this study
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Table 2 Correlation between lipid profile and the studied groups
Group TG (mg/dl) Total Cholesterol(mg/dl) HDL(mg/dl) LDL(mg/dl)
Control 62.3 ± 3.99 55.6 ± 2.2 28.4 ± 1.32 44.3 ± 2.4
ginseng 58.5 ± 4.6 61.7 ± 3.5 33.2 ± 2.1 48.1 ± 2.8
CCl4 98.2 ± 3.5*#$ 127.5 ± 6.5*#$ 23.2 ± 1.54 93.5 ± 2.8*#$
CCl4+ ginseng 70.2 ± 3.54 70.67 ± 5.3 33.2 ± 3.32 50.2 ± 2.1
Values are the means ± SE (n = 10). *, # and $ indicate a significant change from control, ginseng, and CCl4 + ginseng groups, respectively (p <0.05 using ANOVA
followed by Tukey—Kramer as a post ANOVA test)
Fig. 2 Light micrographs of liver sections of rat. Specimens were fixed in 10% neutral formalin and stained with Masson Trichrome. a-b Control
rat (GI). a Control rat (GI) with poorly defined classical hepatic lobules and central veins (Cv) (magnification 100x). b: A hexagonal hepatocyte with
central nucleus (N) and prominent nucleolus (Nu) arranged in strands around the central vein (Cv) and blood sinusoids (Bs) (magnification 400x).
c-g Rats treated with CCl4 (GIII). e Hydropic degeneration and vacuolated hepatocytes. (N) Nuclei, (V) vacuoles. A marked increase in collagen
fibers (arrows) around a congested central vein (Cv) and degenerated hepatocytes with nuclei (N) (magnification 1000x). f Fatty changes liver
(stars) and collapsed sinusoids. f: Collagen fibers (arrows) around collapsed sinusoids. An increase in binucleated hepatocytes (stars) and vacuoles
(V) was observed (magnification 1000x). g Fibrosis in the portal area (arrows). (Hv) hepatic portal vein, (Ha) hepatic artery, and (Bd) proliferated
bile duct (magnification 400x). h Ginseng supplementation with CCl4 (GIV) reduced the accumulation of collagen fibers after CCl4 administration.
(Cv) central veins, (arrows) blood sinusoids (magnification 400x). i Nearly normal hepatic strands and hepatocytes of GIV with nuclei (N) and
nucleoli (Nu), and the reduction of perisinusoidal collagen fibers. Bs: blood sinusoids (magnification 1000x)
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in a significant decrease in the expression of TGF-β and its
receptors (p <0.002).
The effect of CCl4, ginseng, and CCl4 + ginseng on
Smad2, Smad3, and Smad4 expression is shown in
Fig. 4. The administration of CCl4 for 8 weeks in-
creased the expression of Smad2, Smad3 and Smad4
by 2.2-, 5.8- and 4.8-fold, respectively, compared with
the control group (p <0.001). Interestingly, the admin-
istration of ginseng in combination with CCl4 signifi-
cantly decreased the expression of Smad2, Smad3 and
Smad4 by 7-, 3.5- and 5.1-fold, respectively, compared
with the CCl4 group (p <0.001).
The effects of CCl4, ginseng, and CCl4 + ginseng on
MMP2, MMP9, and TIMP-1 gene expression are shown
in Fig. 5. The administration of CCl4 for 8 weeks increased
the expression of MMP2, MMP9, and TIMP-1 by 5.4-,
4.6- and 7.2-fold, respectively, compared with the control
group (p <0.001). However, the administration of CCl4 +
ginseng significant decreased the expression of MMP2,
MMP9, and TIMP-1 by 5-, 4.3- and 6.7-fold, respectively,
compared with the CCl4 group (p <0.0001). No significant
difference was observed for gene expression in the CCl4 +
ginseng group compared with the control group.
The effect of CCl4, ginseng, and CCl4 + ginseng on
Col1a2 and Col3a1 gene expression is shown in
Fig. 6a and b. The administration of CCl4 for 8 weeks
significantly increased the expression of Col1a2 9.5-
fold compared with the control group (p <0.001). The
administration of CCl4 increased the expression of
Col3a1 8.3-fold (p <0.001). However, the administra-
tion of CCl4 + ginseng significantly restored the alter-
ation in these genes compared with the CCl4 group.
The effect of CCl4, ginseng, and CCl4 + ginseng on IL-
10 and IL-8 gene expression is shown in Fig. 7a and b.
The administration of CCl4 for 8 weeks significantly de-
creased the expression of IL-10 4-fold compared with
the control group (p <0.05). The administration of CCl4
increased the expression of IL-8 5.4-fold (p <0.01). How-
ever, the administration of CCl4 + ginseng significantly
restored the alteration in these genes compared with the
CCl4 group. No significant difference in gene expression
was observed in the CCl4 + ginseng group compared
with the control group.
Discussion
The liver is the first line of protection against hepatic
damage induced by xenobiotics and drugs, which can
cause hepatic necrosis and apoptosis [28]. Reactive oxy-
gen species cause direct tissue damage and initiate in-
flammation through the activation of various cytokines
[29]. Lipid peroxidation and free radicals cause the ne-
crosis of hepatocytes, induce inflammation, and promote
the progression of hepatic fibrogenesis [30].
CCl4 is used to induce hepatic fibrosis in experimental
rat models, and several studies have focused on the pre-




































































































































Fig. 3 Effect of CCl4, ginseng, and CCl4 + ginseng on the expression of TGF-β (A), TβF-I (B) and TβF-II (C) genes in the liver. Data are the mean ±
SEM (n = 10). *, # and $ indicate a significant change from the control, ginseng, and CCl4 + ginseng groups, respectively (p <0.05 using ANOVA
followed by Tukey—Kramer as a post ANOVA test)
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Fig. 5 Effect of CCl4, ginseng, and CCl4 + ginseng on the expression of MMP2 (a), MMP9 (b) and TIMP-1 (c) genes in the liver. Data are the mean
± SEM (n = 10). *, # and $ indicate a significant change from the control, ginseng, and CCl4 + ginseng groups, respectively (p <0.05 using ANOVA





















































































































Fig. 4 Effect of CCl4, ginseng, and CCl4 + ginseng on the expression of Smad2 (A), Smad3 (B) and Smad4 (C) in the liver. Data are the mean ± SEM
(n = 10). *, # and $ indicate a significant change from the control, ginseng, and CCl4 + ginseng, groups, respectively (p <0.05 using ANOVA
followed by Tukey—Kramer as a post ANOVA test)
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used to investigate the liver injury associated with oxida-
tive stress and free radicals. Ginseng extract contains
Rb1, Rb2, Rc, Rd, Re, and Rg1 that have a major role in
hepato-protection by suppressing oxidative stress and
lipid peroxides via inhibition of the expression and activ-
ity of cytochrome P450 in the liver [34].
The leakage of hepatocellular enzymes is used as a
hepatotoxicity marker. The current study showed signifi-
cant increases in the serum levels of ALT, AST, total
cholesterol, triglyceride, LDL, and a significant decrease
in HDL following CCl4 administration. However, in the
CCl4 + ginseng group, the levels of ALT and AST were
restored to their normal levels. These results indicate
that ginseng protects against CCl4-induced hepatic dam-
age. Similar previous studies demonstrated that ginseng
extract had antioxidant activity and acted as a free rad-
ical scavenger [34, 35]. Importantly, the increased levels
of triglycerides, total cholesterol, and LDL and the de-
creased level of HDL were restored to their normal
values with CCl4 + ginseng.
IL-8 is as a major factor of acute inflammation [36].
High IL-8 levels in the liver are observed during acute
liver injury [37, 38]. In the present study, CCl4 increased
the expression of IL-8. A similar study found that serum
IL-8 levels were significantly elevated in chronic liver
disease patients. IL-8 serum levels were also associated
with the progression of fibrosis [39]. Therefore, IL-8
overexpression might be related to tissue damage [40,
41]. In the current study, a high expression of IL-8 was
observed in association with CCl4, and the administra-
tion of ginseng extract decreased IL-8 levels to normal
values indicating the anti-inflammatory effects of gin-
seng extract.
IL-10 is a cytokine produced by cells of the immune sys-
tem as well as liver cells including hepatocytes, sinusoidal
cells, Kupffer cells, stellate cells, and liver-associated lym-
phocytes [42]. It was reported that endogenous IL-10
decreased intrahepatic inflammatory responses and fibro-
sis in several models of liver injury [43]. In the current
study, the down-regulation of Il-10 induced by CCl4 lead
Fig. 6 Effect of CCl4, ginseng, and CCl4 + ginseng on the expression of Collagen 1a2 (a) and Collagen 3a1 (b) genes in the rat liver. Data are the
mean ± SEM (n = 10). *, # and $ indicate a significant change from the control, ginseng, and CCl4 + ginseng groups, respectively (p <0.05 using













































































Fig. 7 Effect of CCl4, ginseng, and CCl4 + ginseng on the expression of IL-10 (a) and IL-8 (b) genes in the liver. Data are the mean ± SEM (n = 10). *, #
and $ indicate a significant change from the control, ginseng, and CCl4 + ginseng groups, respectively (p <0.05 using ANOVA followed by
Tukey—Kramer as a post ANOVA test)
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to the overexpression of collagen types I and III. Another
study found that collagen types I and III were significantly
decreased to normal values at 3 weeks after IL-10 treat-
ment. Furthermore, the high expressions of MMP2 and
TIMP-1 induced by CCl4 were significantly decreased
after 3 weeks of IL-10 treatment, indicating that collagen
types I and III might be associated with a decrease in
MMP-2 and TIMP-1 levels[44]. In the current study, gin-
seng extract increased the expression of IL-10, which was
associated with a decrease in MMP-2, -9 and MIT-1 and a
decrease in the expression of collagen types I and III.
These results indicated that exogenous IL-10 might have a
therapeutic effect on advanced liver fibrosis.
Hydroxyproline, a major constituent of collagen, is a
good marker for ECM accumulation [45]. The overex-
pression of type I, III and IV collagen are early events in
the development of CCl4-induced hepatic fibrosis. Type
I and III collagen fibers are localized around the portal
area and are markedly increased around the tributaries
of portal veins. In the current study, histological analysis
of liver from the CCl4 group showed fibrosis around the
central veins, portal area, and perisinusoidal space. In
the current study, livers in the CCl4 group showed fibro-
sis of the central veins as indicated by collagen fibers in
the portal area and highly proliferated bile duct, necrotic
disorganized hepatic strands, hyalinization of cytoplasm
and vacuolated hepatocytes. In addition, the results of
the present study are in agreement with a study by
Iredale et al., that reported mild fatty change and the
vacuolization of hepatocytes after the intraperitoneal
injection of rats with CCl4 [46].
In the present study, CCl4 increased the expression of
collagen 1a1 and collagen 1a III. A similar study re-
ported the increased expression of collagen types I and
II after CCl4 administration [47]. These findings were
consistent with those of Yu et al., who reported that the
overexpression of type I, III and IV collagen were early
events in the development of CCl4-induced hepatic
fibrosis in rats. Type I and III collagen fibers are local-
ized around the portal area [45] and are markedly in-
creased around the tributaries of portal veins [47]. The
overexpression of COL1A1 and CL1AIII leads to en-
hanced collagenous matrix deposition in liver. The CCl4
+ ginseng group had a reduced accumulation of collagen
fibers compared with the CCl4 group. Similarly, in the
present study, the administration of ginseng extract
reduced the expression of collagens type I and II.
Extracellular matrix (ECM) accumulation is a common
phenomenon in liver fibrosis. MMPs and TIMPs are a
class of secreted enzymes with important functions in
ECM degradation [48] and MMPs are associated with
liver fibrosis. MMPs and their tissue inhibitors were ele-
vated quickly after CCl4-induced liver injury in rats, and
the hepatic expression of MMP-3 was detected as early
as 6 h after CCl4 administration in rats. In the current
study, the administration of CCl4 caused an overexpres-
sion of MMP-2, -9, and TIMP-1. Similarly, Knittel et al.,
reported MMP and TIMP overexpression during liver
injury and fibrosis after a single dose of CCl4, and that
MMP-2, MMP-3, MMP-9, MMP-10, MMP-13, and
MT1-MMP were all overexpressed [49]. In a rat model
of hepatic fibrosis induced by bile duct ligation (BDL),
MMP-2 and MMP-9 were increased suggesting that
continued tissue damage and inflammation induced
MMP expression [50]. Therefore, MMPs might be asso-
ciated with liver fibrosis. In the present study, ginseng
administration with CCl4 decreased the expressions of
MMP-2, -9 and TIMP-1 to their normal levels similar to
that in the control group. Similarly, Lo et al., found that
ginsenoside significantly reduced the expression of
MMP-2, -9 and TIMP-1 in HSC-T6 cells after induction
with H2O2. They suggested that ginsenoside had an anti-
fibrotic effect on HSCs by inhibiting the activation, pro-
liferation, and expression of collagen, TGF-β1, MMP-2,
and TIMP-1 [51].
The pathogenesis of fibrosis involves several mecha-
nisms such as the inflammatory, growth factor signaling,
and lipid signaling pathways. The inflammatory pathway
and the growth factor signaling pathway mediated by
TGF-β are the most important pathways for fibrosis
[52]. Transforming growth factor-β is involved in various
physiologic processes; therefore, understanding the mo-
lecular mechanisms involved in TGF-β signaling in dis-
eases is important for the development of its therapies.
The regulation of extra-cellular matrix accumulation by
fibrogenic transforming growth factor (TGF)-β signals
involves different mechanisms dependent upon whether
there is acute or chronic liver damage. Hepatic stellate
cells (HSC) are the principal effector cell type in this
pathway. After acute liver injury, TGF-β enhances colla-
gen synthesis by activating hepatic stellate cells via the
Smad pathways. Activated TGF-β mediates the activa-
tion of Smad2, Smad3, and Smad4 in a fibrotic rat model
[53]. In the present study, CCl4 increased Smad2,
Smad3, and Smad4 expression, and ginseng extract re-
stored their expression to normal levels and decreased
histological fibrosis. These results indicate that Smad2,
Smad3, and Smad4 have a significant role in the pro-
gression of liver fibrosis. A similar study found that the
high expression of Smad-2 and Smad-4 was associated
with liver fibrosis in rats using in situ hybridization [54].
TGF-β1 is a pro-fibrogenic cytokine in hepatic fibrosis
[47]. Activated TGF‐β1 signal to the cells through its
trans-membrane receptors TβR‐I and TβR‐II. In the
present study, CCl4 administration increased the expres-
sion of TGF-β1 and its receptors TβR-1, and TβR-1I.
The increased TGF-β1, TβR-1, and TβR-II expressions
were restored to their normal values after ginseng
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treatment. A similar study found that CCl4 administra-
tion increased TGF-β1 protein levels, and its receptor
levels, and this alteration in protein expression was re-
stored by Gypenosides [55]. Another study reported that
TGF-β1 activity was increased in rats administered a
single dose of 20% CCl4 in olive oil, and this increase
was restored by a low-dose of herbal extract [56].
Another study proposed that suppressing TGF-β-
induced Smad2/Smad3 phosphorylation and nuclear
translocation in HSCs attenuated fibrosis [55].
When TGF‐β1 binds to it receptors (TβR‐I and TβR‐
II), it catalyzes Smad2/Smad3, which enters the nucleus,
binds to transcriptional factors and regulates the expres-
sion of collagen and TIMP genes [24, 25]. In the current
study, the expressions of TGF‐β1, TβR‐I, TβR‐II, Smad2,
and Smad3 were significantly increased in the CCl4
group compared with the normal group. This indicated
that the TGF‐β1/Smad signaling pathway was activated
during liver fibrosis. ginseng extract administration
decreased Smad2, Smad3, TβR‐I, TβR‐II, and TGF‐β1
expression to their normal values.
Conclusions
Ginseng extract had an anti‐fibrosis effect in a CCl4‐in-
duced liver fibrosis model by regulating the TGF‐β1/
Smad signaling pathway via the inhibition of Smad3,
Smad2, and TGF‐β1 expression.
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